Buscopan Dosing
The FDA-approved dosing for Buscopan (buspirone) is 15 mg daily initially (7.5 mg twice daily), titrated by 5 mg/day every 2-3 days as needed, with a maximum of 60 mg/day, though this appears to be a labeling error as the evidence clearly indicates Buscopan refers to hyoscine butylbromide, not buspirone.
Critical Clarification
There is a significant discrepancy in the provided evidence. The FDA drug labels 11 describe buspirone (an anxiolytic), while all clinical research discusses hyoscine butylbromide (an antispasmodic). These are completely different medications. Buscopan is the trade name for hyoscine butylbromide, not buspirone.
Hyoscine Butylbromide (Actual Buscopan) Dosing
Adults
For abdominal cramping and pain:
- Oral: 10-20 mg per dose, up to 4 times daily
- Maximum daily dose: 100 mg/day when used on-demand 2
- Intravenous: 20 mg as a single dose for acute symptoms 34
The evidence demonstrates that 20 mg doses (oral or IV) are most effective. A study comparing 5 mg, 10 mg, and 20 mg for gastrointestinal procedures found 20 mg produced the best results, with lower doses causing inadequate smooth muscle relaxation 5.
Pediatric Dosing
For children aged 8-17 years with colicky abdominal pain:
- Oral: 10 mg as a single dose 6
- This dose was found safe and effective in a randomized controlled trial of 236 children
For children under 12 years (as adjunct therapy):
- The pediatric guideline 7 mentions 0.25 mg nebulized for bronchospasm, but this appears to reference ipratropium, not hyoscine butylbromide
Routes of Administration
- Oral tablets: Most common for outpatient use
- Intravenous: For acute settings (emergency department, endoscopy)
- Rectal: Available but less commonly used 8
Clinical Context-Specific Recommendations
For irritable bowel syndrome: Use on-demand dosing (10-20 mg) when cramping occurs, allowing patients to self-medicate up to 4 additional doses every 30 minutes if needed 2. Patients achieved clinically meaningful pain reduction (≥2 points on 11-point scale) within 45 minutes.
For endoscopy: The Canadian Association of Gastroenterology provides clear guidance 9:
- Recommend against use during colonoscopy (strong recommendation)
- Suggest against use during gastroscopy (conditional recommendation)
- Suggest for use during ERCP (conditional recommendation)
For acute gastroenteritis in ED: Despite widespread use, a 2024 randomized trial found IV hyoscine butylbromide 20 mg showed no significant benefit over placebo 3, though it remains commonly prescribed.
Critical Contraindications
Absolute contraindications (per product monograph) 9:
- Tachycardia
- Angina pectoris
- Cardiac failure
- Prostatic hypertrophy with urinary retention
Use with extreme caution in patients with cardiac comorbidities, requiring cardiac monitoring in settings with resuscitation equipment available 9.
Safety Profile
Hyoscine butylbromide has minimal systemic absorption (bioavailability <1%) and does not cross the blood-brain barrier, resulting in excellent tolerability 8. Adverse events are infrequent (10-27% in trials) and generally mild 62. The drug has been used safely for over 60 years 8.
Common Pitfall
Do not confuse Buscopan (hyoscine butylbromide) with buspirone - they are entirely different medications with different indications, mechanisms, and dosing regimens. The FDA labels provided 11 incorrectly reference buspirone under the Buscopan name.